{
  "docId": "019de071-d756-7568-8588-410684bab010",
  "docSlug": "c18c99fc10f671fc397f8a743cdc0ce4",
  "documentTitle": "Aeglea BioTherapeutics | Results Presentation Deck | 23 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 23,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a structured layout to present three key pillars of clinical success: efficacy, functional outcome, and safety.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-d756-7568-8588-410684bab010/5",
  "deckHref": "/decks/019de071-d756-7568-8588-410684bab010",
  "deckJsonHref": "/decks/019de071-d756-7568-8588-410684bab010.json",
  "deckAnchorHref": "/decks/019de071-d756-7568-8588-410684bab010#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Lowering Plasma Arginine Accompanied by Improvement in Mobility. Pivotal Data Supports Planned BLA Submission in First Half of 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea2b886b-1cb4-4768-bb1d-995431ca6bdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "Favorable Safety Profile: Consistent with previous trials; no treatment discontinuations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "405d2c4f-9c1e-4b4b-9e42-139cd88404c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.06,
        "y": 0.4
      },
      "kind": "list",
      "text": "Impact on Mobility: GMFM-E mean score improved by 4.2 units vs 0.4 worsening in placebo.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70c3761a-4a61-4ddf-a6ba-a97a98fe8311",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.06,
        "y": 0.0015
      },
      "kind": "list",
      "text": "Substantial Reduction in Plasma Arginine: 80% reduction at 24 weeks; 90.5% of patients achieved normal levels.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cba23390-1a7b-42e7-9d86-cdba457d0ca8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.88,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "GMFM-E = Gross Motor Function Measure Part E; ARG1-D = Arginase 1 Deficiency",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eedd156-2a46-456c-902d-72ecdb7e9a87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.88,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "First Potential Therapy to Normalize Plasma Arginine Levels in ARG1-D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6b3c9f5-6a89-4f18-97f0-ee3652073626",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 5,
      "beatId": "e0d16f2c-c175-4c6a-8d80-f841a8242c55",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides present Pegzilarginase's efficacy in reducing arginine levels and improving mobility.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 5,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "81d36eb9-c56a-4571-9f51-feb9c7f6295f",
      "evidence": "Presents Pegzilarginase's benefits in managing arginine levels and improving patient outcomes.",
      "position": 1,
      "objective": "Demonstrates how Pegzilarginase meets the need for effective arginine reduction",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}